Literature DB >> 17940956

Regions in Ebola virus VP24 that are important for nucleocapsid formation.

Takeshi Noda1, Peter Halfmann, Hiroshi Sagara, Yoshihiro Kawaoka.   

Abstract

Ebola virus (EBOV) VP24, together with nucleoprotein and VP35, is an essential component of viral RNA-protein complexes called "nucleocapsids." In this study, using a series of deletion mutants of VP24, we identified regions within VP24 that are important for the formation of nucleocapsid-like structures and determined that both termini of VP24 are essential for nucleocapsid formation. This finding advances our knowledge of both EBOV morphogenesis and the nature of VP24 molecules in nucleocapsid formation, which will be useful for the development of antiviral compounds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940956     DOI: 10.1086/520596

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Authors:  Kevin B Spurgers; Tim Alefantis; Brian D Peyser; Gordon T Ruthel; Alison A Bergeron; Julie A Costantino; Sven Enterlein; Krishna P Kota; R C Dutch Boltz; M Javad Aman; Vito G Delvecchio; Sina Bavari
Journal:  Mol Cell Proteomics       Date:  2010-08-11       Impact factor: 5.911

Review 2.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

3.  The ebolavirus VP24 interferon antagonist: know your enemy.

Authors:  Adrianna P P Zhang; Dafna M Abelson; Zachary A Bornholdt; Tong Liu; Virgil L Woods; Erica Ollmann Saphire
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

4.  Inclusion bodies are a site of ebolavirus replication.

Authors:  Thomas Hoenen; Reed S Shabman; Allison Groseth; Astrid Herwig; Michaela Weber; Gordian Schudt; Olga Dolnik; Christopher F Basler; Stephan Becker; Heinz Feldmann
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

5.  Contribution of Sec61α to the life cycle of Ebola virus.

Authors:  Ayaka Iwasa; Peter Halfmann; Takeshi Noda; Masaaki Oyama; Hiroko Kozuka-Hata; Shinji Watanabe; Masayuki Shimojima; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin α1 and partially alters its nuclear import.

Authors:  Reed S Shabman; Erol E Gulcicek; Kathryn L Stone; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Authors:  Kathleen C Prins; Sebastien Delpeut; Daisy W Leung; Olivier Reynard; Valentina A Volchkova; St Patrick Reid; Parameshwaran Ramanan; Washington B Cárdenas; Gaya K Amarasinghe; Viktor E Volchkov; Christopher F Basler
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

8.  A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity.

Authors:  Ari Watt; Felicien Moukambi; Logan Banadyga; Allison Groseth; Julie Callison; Astrid Herwig; Hideki Ebihara; Heinz Feldmann; Thomas Hoenen
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

9.  Dimerization Controls Marburg Virus VP24-dependent Modulation of Host Antioxidative Stress Responses.

Authors:  Britney Johnson; Jing Li; Jagat Adhikari; Megan R Edwards; Hao Zhang; Toni Schwarz; Daisy W Leung; Christopher F Basler; Michael L Gross; Gaya K Amarasinghe
Journal:  J Mol Biol       Date:  2016-08-04       Impact factor: 5.469

10.  Marburg virus evades interferon responses by a mechanism distinct from ebola virus.

Authors:  Charalampos Valmas; Melanie N Grosch; Michael Schümann; Judith Olejnik; Osvaldo Martinez; Sonja M Best; Verena Krähling; Christopher F Basler; Elke Mühlberger
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.